What are lipotropic (MIC) injections, and what does the evidence show?

What "lipotropic" means

In nutrition research, a lipotrope is a compound that, in animal studies, speeds the removal of fat from the liver or reduces fat deposits in the liver.[1] A 2013 review of lipotropes in plant foods (Fardet and Chardigny) lists choline, betaine, myo-inositol, methionine and carnitine as the main ones.[1] Fardet and Chardigny's 2013 review surveyed rat studies of plant compounds that may be lipotropic and says the finding 'remains to be confirmed in humans, for whom intervention studies are practically non-existent.'[1]

'Lipotropic' describes an effect on liver fat seen in animals; the word does not mean that a product burns body fat or causes weight loss in people.

What studies in people found

Studies that name the blend or lipotropic nutrients

In searches of PubMed, Europe PMC and ClinicalTrials.gov on October 8, 2026, we found no study in people, among the records we could read, that tested a lipotropic (MIC) injection, a blend of methionine, inositol and choline, for weight loss or body fat. The same searches returned papers that we could not read, including a 1964 paper in Polish about a vitamin preparation given to people with hardening of the arteries.[2] The database holds no abstract for that paper, so we cannot say what it tested or found.[2] A further PubMed search on October 8, 2026, of records indexed under both lipotropic agents and injections, returned a 1961 paper whose title describes an injection and blood cholesterol levels.[3] The database holds no abstract for the 1961 paper either, so we could not read it.[3]

The PubMed search of October 8, 2026 returned a randomized trial of a product described as containing 'lipotropic nutrients'. The paper's title calls that product a 'natural dietary compound', and it was not an injection.[4] In the 1998 trial (Hoeger and colleagues), 123 adults on a 4-week program of 1,500 kcal a day and walking were randomly assigned to the product (56 people) or a placebo (67 people).[4] The abstract of Hoeger 1998 reports significant differences between the groups in body fat percentage, fat mass and fat-free mass, and no significant difference in body weight or BMI.[4] The product in Hoeger 1998 also contained chromium picolinate, inulin, capsicum and L-phenylalanine, and the abstract does not say which lipotropic nutrients were in it.[4]

L-carnitine into a vein during a fast

L-carnitine, a nutrient that Fardet and Chardigny's 2013 review lists among the lipotropes, was tested by injection in a small 2014 trial in China (Zhang and colleagues).[1][5] Thirty adults with metabolic syndrome and a BMI of 25 or more went through a 7-day fasting program at a university hospital, with 2 days on 700 to 800 kcal and 5 days on about 200 kcal a day, followed by 3 days of stepwise return to a normal diet; 15 were randomly assigned to 4 g of L-carnitine into a vein each day and 15 to saline.[5]

In Zhang 2014, the L-carnitine group lost an average of 4.6 kg over the 7 days and the saline group 3.2 kg, a statistically significant difference of 1.4 kg. Waist size in Zhang 2014 fell by an average of 5.0 cm with L-carnitine and 1.7 cm with saline.[5]

Zhang 2014 was a single-blind pilot trial that lasted 7 days and reports no measurement after day 7. The authors of Zhang 2014 name the small number of patients and the lack of any measure of fat loss or lean mass as its main limits. The paper lists a company, Guangzhou Enter Nutr Bioscience Co., Ltd., as one of two sources of support.[5]

Zhang 2014 tested L-carnitine alone, given into a vein twice a day during a near-fast. It did not test a blend of methionine, inositol and choline, and it did not test injections given without a fast.[5]

A 2019 study that shares authors with the 2014 trial (Zhang T and colleagues) looked back at hospital records and was not randomized.[6] Of 192 patients who finished fasting therapy between September 2008 and July 2018, 142 had been given L-carnitine into a vein; after the researchers matched patients on their characteristics, 40 were compared in each group.[6] The abstract of the 2019 study reports an average weight loss of 4.05 kg with L-carnitine and 3.25 kg without it, a statistically significant difference of 0.8 kg, and larger falls in diastolic blood pressure and triglycerides in the group without L-carnitine.[6] The abstract names no source of funding.[6]

L-carnitine in pooled trials

A 2020 meta-analysis that included 37 randomized trials in which people were given L-carnitine (Talenezhad and colleagues) found an average of 1.21 kg more weight loss with L-carnitine than in comparison groups (95% confidence interval 0.68 to 1.73 kg), pooled falls in BMI and fat mass, and no significant effect on waist size or body fat percentage.[7] The abstract of Talenezhad 2020 adds that only the body weight result held when the analysis was limited to high-quality trials.[7]

A 2016 systematic review that included nine randomized trials with 911 participants in total (Pooyandjoo and colleagues) found an average of 1.33 kg more weight loss with carnitine than in control groups (95% confidence interval 0.57 to 2.09 kg).[8] Pooyandjoo 2016 also reports that the weight difference got smaller the longer carnitine was taken.[8]

The abstracts of Talenezhad 2020 and Pooyandjoo 2016 report no separate result for injected L-carnitine, so their pooled figures cannot be read as results for an injection.[7][8]

Inositol and choline

For inositol, we read one systematic review, which is about polycystic ovary syndrome (PCOS), and the abstracts of two randomized trials in other groups of people. A 2024 systematic review written to inform the 2023 international PCOS guideline (Fitz and colleagues) included 30 trials with 2,230 participants and concluded: 'The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive.'[9] A review about PCOS does not show that inositol causes weight loss in people without PCOS. A PubMed search on October 8, 2026 also returned randomized trials of inositol in people without PCOS, including trials in pregnant women that we did not read.

In a 2012 trial (Santamaria and colleagues), 80 postmenopausal women with metabolic syndrome were enrolled, all were put on a low-energy diet, and they were randomly assigned to 2 g of myo-inositol twice a day (40 women) or a placebo (40 women) for 12 months.[10] The abstract of Santamaria 2012 reports no significant improvement in BMI or waist size with myo-inositol compared with placebo, and significant improvements in the other measures it lists, including blood sugar, insulin, triglycerides and blood pressure.[10] The abstract of Santamaria 2012 names no source of funding, does not say how the myo-inositol was given and does not mention an injection.[10]

In a 2025 double-blind trial in northern Italy (Antoniotti and colleagues), 56 patients aged 10 to 18 with obesity and insulin resistance were randomly assigned to a mix of 2,000 mg of myo-inositol, 5 mg of zinc gluconate and 1,000 mg of galactooligosaccharides, or to a placebo that held the galactooligosaccharides alone, for 3 months; all followed a Mediterranean-style diet, and 50 completed the trial.[11] The abstract of Antoniotti 2025 reports no improvement in insulin resistance, the trial's main outcome, a better HDL cholesterol level with the mix, and lower fasting insulin in an analysis by obesity grade that was run after the main one.[11] The abstract of Antoniotti 2025 gives no result for weight, BMI or waist size.[11] The mix combined myo-inositol with zinc, so Antoniotti 2025 cannot show what myo-inositol does by itself.[11] The PubMed record of Antoniotti 2025 lists a foundation, a university and a company, DIFASS International S.p.a, as funders, and the abstract does not say how the mix was given or mention an injection.[11]

For choline and weight, we read a small 2014 study of tablets (Elsawy and colleagues).[12] Twenty-two female taekwondo and judo athletes were divided into two groups by body mass; 10 took 2 g of choline a day as tablets for the week before a competition and 12 took a placebo.[12] Table 2 of Elsawy 2014 shows body fat percentage going from 18.76% to 16.84% with choline and from 18.52% to 17.77% with placebo, and BMI falling in both groups.[12] The authors of Elsawy 2014 report a significant difference in body fat for the choline group and no significant difference in BMI between the two groups.[12] Elsawy 2014 was small and short, formed its groups by body mass, and tested tablets in athletes before a competition.[12]

How far these results go

The studies of single ingredients that we read are mostly small or short trials, one look back at hospital records, and pooled reviews that we read as abstracts. A result for one ingredient taken by mouth, or given into a vein in a different setting, does not show what a lipotropic injection does.

Other claims clinics make

For choline and liver fat, we read the abstracts of randomized trials in two settings: adults fed through a vein, and people with fatty liver disease who were given mixes of several nutrients. In a 2001 trial (Buchman and colleagues), 15 adults who got at least 80% of their nutrition by IV feeding were randomly assigned to their usual feed (8 people) or the same feed with 2 g of choline chloride added (7 people) for 24 weeks.[13] The abstract of Buchman 2001 reports no significant differences at 2 weeks, a significant difference in a CT scan measure of liver fat from week 4 through week 24, and lower blood levels of the liver enzyme ALT in the choline group at weeks 6, 12, 20 and 24.[13] Buchman 2001 also reports that fatty liver had returned at week 34, 10 weeks after the choline was stopped.[13]

An earlier trial (Buchman and colleagues, 1992) drew on 15 adults on long-term IV feeding at home who had low blood choline; patients were given lecithin by mouth or a placebo for 6 weeks in a double-blind randomized trial, and the abstract does not give the size of each group.[14] The abstract of Buchman 1992 reports that blood choline rose with lecithin, that a CT scan measure of liver fat improved at 2 and 6 weeks in the lecithin group, and that changes in the placebo group were not significant.[14] The PubMed record of Buchman 1992 lists a U.S. Public Health Service grant.[14]

In a 2017 randomized trial (Zöhrer and colleagues), children and adolescents with nonalcoholic steatohepatitis (NASH), a form of fatty liver disease, confirmed by biopsy were assigned to lifestyle changes with a placebo or lifestyle changes with a mix of docosahexaenoic acid (DHA, an omega-3 fat), choline and vitamin E; 40 took part in the whole trial.[15] The abstract of Zöhrer 2017 reports that severe fatty liver fell from 50% to 5% in the group given the mix, and that the liver enzyme ALT and fasting blood sugar improved only in that group.[15] The abstract of Zöhrer 2017 gives no figure for fatty liver in the placebo group, names no source of funding and does not say how the mix was given.[15]

A 2020 trial in adults with nonalcoholic fatty liver disease (Cerletti and colleagues) tested a mix of DHA, phosphatidylcholine, silymarin, choline, curcumin and a form of vitamin E against a control for 3 months, with tests completed on 113 people.[16] The abstract of Cerletti 2020 reports no difference between the groups in liver enzymes and a slight rise in cholesterol and blood sugar after the mix.[16] It gives no measure of liver fat and says the trial 'failed to demonstrate any efficacy on relevant physiopathological markers.'[16] A 2024 pilot trial in adults with obesity and metabolic syndrome (Perva and colleagues) tested a mix of seven nutrients that included 500 mg of choline bitartrate a day, given as capsules and oils, against a placebo for 3 months.[17] In Perva 2024, 196 people were randomly assigned, 155 reached the end, and the paper says 39 had the liver scan at both visits.[17] Perva 2024 reports that a scan measure of liver fat went from a median of 355 to 332 dB/m in the group given the mix, a significant change, and from 318 to 334 dB/m in the placebo group, a change that was not significant.[17] The authors of Perva 2024 write that 'the statistical significance of the results reported in this study should be considered with caution.'[17] Perva 2024 names a research project called NutriGen as its funder, and one of its authors was employed by a company, Advanced Nutrigenomics LLC.[17]

Buchman 2001 and Buchman 1992 studied people who depended on IV feeding, a group that Buchman 2001 describes as often having low blood choline.[13][14] Zöhrer 2017, Cerletti 2020 and Perva 2024 gave choline together with other nutrients, so they cannot show what choline did by itself.[15][16][17] None of these five trials shows that a choline injection changes liver fat in people who eat a normal diet.

In Zhang 2014, the 7-day fasting trial of 30 adults with metabolic syndrome, fatigue scores fell in the group given L-carnitine into a vein and rose in the saline group. That result in Zhang 2014 is about tiredness during a near-fast and does not show an effect on energy in daily life.[5]

A 1987 double-blind crossover trial (Drăgan and colleagues) gave 17 elite swimmers 1 g of L-carnitine into a vein or a placebo, and its abstract reports significant changes in blood fats, lactic acid after exercise and a muscle-response reading 90 to 120 minutes later. The abstract of Drăgan 1987 reports no measure of tiredness, performance or body weight.[18]

A nutrient's part in how cells handle fat is not evidence that injecting the nutrient changes a person's weight, energy level or metabolic rate.

Evidence at a glance

Evidence levels in this table follow our grading key: Emerging means some controlled human evidence that falls short of consistent results from randomized trials, such as a small, short or single trial, mixed results, or results for lab measures only; and 'no support found' means the searches named in that row found no study that supports the claim.

In this table, Not published means the searches named in the same row found no published study for that cell.

Side effects and risks

The studies we read did not test an injection that combines methionine, inositol and choline, so we have no trial data on how often side effects happen with lipotropic injections.

A 2006 review of methionine toxicity in people (Garlick) says that nutrition and metabolism studies using methionine at amounts below and above the requirement 'have not reported adverse effects in adults and children.'[19] Garlick 2006 calls methionine's role as a precursor of homocysteine 'the most notable cause for concern' and reports raised homocysteine at dietary intakes above 5 times normal.[19] Garlick 2006 also reports a death after a methionine test dose was mistakenly given at 10 times the intended size.[19] The abstract of Garlick 2006 gives no data on injected methionine.[19]

A 2011 review of inositol safety (Carlomagno and Unfer) reports that only the highest dose of myo-inositol it covered, 12 g a day, 'induced mild gastrointestinal side effects such as nausea, flatus and diarrhea.'[20] The abstract of Carlomagno and Unfer 2011 does not say how the inositol was given.[20]

In Zhang 2014, the 7-day fasting trial, 2 of the 15 people given L-carnitine into a vein reported brief nausea, one person in each group had mild bleeding from the gums, and one woman in the saline group had an early period.[5] Zhang 2014 reports no low blood sugar or other severe reaction.[5]

Anyone with a medical condition, or taking other medicines, should ask a licensed clinician before having a lipotropic injection.

If you have severe symptoms, call 911 or seek emergency care. Report side effects to FDA MedWatch.